White Powder 99% Industrial Grade Octreotide acetate CAS NO (83150-76-9)

1. Introduction to Octreotide Acetate (83150-76-9):

Octreotide acetate, a synthetic analogue of somatostatin, represents a pharmaceutical agent widely used in the management of various endocrine and gastrointestinal disorders. With its potent inhibitory effects on hormone secretion and cell proliferation, octreotide acetate plays a crucial role in the treatment of conditions such as acromegaly, neuroendocrine tumors, and gastrointestinal bleeding.

2. Chemical Composition and Molecular Structure:

Octreotide acetate is derived from the natural peptide hormone somatostatin through chemical modification, specifically acetylation of the N-terminus. This modification enhances the compound's stability and pharmacokinetic properties while preserving its biological activity. The molecular formula of octreotide acetate is C49H66N10O10S2.

3. Mechanism of Action:

Octreotide acetate exerts its pharmacological effects primarily through binding to somatostatin receptors, particularly subtype 2 (SST2), located on various target cells and tissues. By mimicking the inhibitory actions of endogenous somatostatin, octreotide acetate suppresses the release of growth hormone, insulin, glucagon, and other hormones involved in endocrine regulation.

4. Therapeutic Indications:

Octreotide acetate is indicated for the management of several endocrine and gastrointestinal disorders, including acromegaly, carcinoid syndrome, VIPomas, insulinomas, and refractory diarrhea associated with various gastrointestinal conditions. Its ability to modulate hormone secretion and alleviate symptoms makes it a cornerstone therapy for these conditions.

5. Treatment of Acromegaly:

In patients with acromegaly, octreotide acetate helps control excess growth hormone secretion, thereby reducing symptoms such as acral enlargement, soft tissue swelling, and metabolic disturbances. Long-acting formulations of octreotide acetate offer sustained hormone suppression, allowing for convenient dosing regimens and improved patient compliance.

6. Management of Neuroendocrine Tumors:

Octreotide acetate is also employed in the management of neuroendocrine tumors (NETs), including carcinoid tumors, gastrinomas, insulinomas, and glucagonomas. By inhibiting hormone secretion and tumor growth, it helps alleviate symptoms such as flushing, diarrhea, hypoglycemia, and tumor-related complications.

7. Control of Gastrointestinal Bleeding:

In cases of refractory gastrointestinal bleeding, particularly from esophageal varices or gastric ulcers, octreotide acetate can be administered to reduce blood flow and improve hemostasis. Its vasoconstrictive effects on splanchnic circulation help reduce portal hypertension and minimize bleeding episodes in these patients.

8. Formulations and Administration:

Octreotide acetate is available in various formulations for parenteral administration, including short-acting injectables, long-acting depot formulations, and subcutaneous infusion systems. The choice of formulation depends on the specific indication, dosing requirements, and patient preferences.

9. Adverse Effects and Safety Considerations:

Common adverse effects associated with octreotide acetate therapy include gastrointestinal disturbances (e.g., diarrhea, nausea), injection site reactions, gallstones, and alterations in glucose metabolism. Long-term therapy may also be associated with thyroid dysfunction, vitamin B12 deficiency, and changes in cardiac function. Monitoring of electrolytes, glucose levels, and thyroid function is recommended during treatment.

10. Future Research and Clinical Perspectives:

Continued research into the therapeutic potential of octreotide acetate, including its efficacy in various disease states and the development of novel formulations, holds promise for improving patient outcomes and expanding its clinical applications. Further exploration of its mechanisms of action, pharmacokinetics, and combination therapies may lead to new treatment strategies for endocrine and gastrointestinal disorders.